Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America. (2nd May 2019)

• Record Type: Journal Article
• Authors: Nicolle, Lindsay E; Gupta, Kalpana; Bradley, Suzanne F; Colgan, Richard; DeMuri, Gregory P; Drekonja, Dimitri; Eckert, Linda O; Geerlings, Suzanne E; Köves, Béla; Hooton, Thomas M; Juthani-Mehta, Manisha; Knight, Shandra L; Saint, Sanjay; Schaeffer, Anthony J; Trautner, Barbara; Wullt, Bjorn; Siemieniuk, Reed
• Is Part Of: Clinical infectious diseases. Volume 68:Number 10(2019)
• Page Start: 1611
• Page End: 1615
• Publication Date: 2019-05-02
• Subjects: asymptomatic bacteriuria -- bacteriuria -- urinary tract infection -- pyelonephritis -- cystitis -- diabetes -- pregnancy -- renal transplant -- endourologic surgery -- urologic devices -- urinary catheter -- older adults -- nursing home -- long-term care -- spinal cord injury -- neurogenic bladder; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciz021
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: Asymptomatic bacteriuria (ASB) is a common finding in many populations, including healthy women and persons with underlying urologic abnormalities. The 2005 guideline from the Infectious Diseases Society of America recommended that ASB should be screened for and treated only in pregnant women or in an individual prior to undergoing invasive urologic procedures. Treatment was not recommended for healthy women; older women or men; or persons with diabetes, indwelling catheters, or spinal cord injury. The guideline did not address children and some adult populations, including patients with neutropenia, solid organ transplants, and nonurologic surgery. In the years since the publication of the guideline, further information relevant to ASB has become available. In addition, antimicrobial treatment of ASB has been recognized as an important contributor to inappropriate antimicrobial use, which promotes emergence of antimicrobial resistance. The current guideline updates the recommendations of the 2005 guideline, includes new recommendations for populations not previously addressed, and, where relevant, addresses the interpretation of nonlocalizing clinical symptoms in populations with a high prevalence of ASB.